Dyspepsia future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Dyspepsia}} {{CMG}} ==Overview== ==Future or Investigational Therapies== A 2004 meta-analysis pooling data from three double-blind placebo-controlled studies fou...")
 
Line 2: Line 2:
{{Dyspepsia}}
{{Dyspepsia}}
{{CMG}}
{{CMG}}
==Overview==


==Future or Investigational Therapies==
==Future or Investigational Therapies==

Revision as of 19:17, 22 March 2013

Dyspepsia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Dyspepsia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Dyspepsia future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Dyspepsia future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dyspepsia future or investigational therapies

CDC on Dyspepsia future or investigational therapies

Dyspepsia future or investigational therapies in the news

Blogs on Dyspepsia future or investigational therapies

Directions to Hospitals Treating Dyspepsia

Risk calculators and risk factors for Dyspepsia future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

A 2004 meta-analysis pooling data from three double-blind placebo-controlled studies found the multiple herbal extract Iberogast to be significantly more effective than placebo (p value = 0.001) at treating patients with functional dyspepsia through the targeting of multiple dyspeptic pathologies[1]. This German-made phytopharmaceutical was found to be equivalent to cisapride and significantly superior to metochlopramide at reducing the symptoms of functional dyspepsia over a four week period.[2][3] Retrospective surveillance of 40,961 children (12 years and under) found no serious side-effects[4].

References

  1. Melzer J, Rosch W, Reichling J, Brignoli R, Saller R (2004). "Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW-5 (Iberogast)". Aliment Pharmacol Ther. 20: 1279&ndash, 87.
  2. Rosch w, Vinson B, Sassin, I (2002). "A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia". Z Gastroenterol. 40: 401&ndash, 8.
  3. Hanisch J, Bock P, Vinson B (2005). "The efficacy and safety of STW 5 versus Metochlopramide oral for functional dyspepsia under practice conditions (in German)". Med Klinik. 100. Text "pages107" ignored (help)
  4. Liechtle K (1999). "Experience reports on the use of Iberogast in children (in German)". Forschungsbericht Steigerwald Arzneimittelwerk. GmbH.